Use of evidence-based pharmacotherapy after myocardial infarction in Estonia
<p>Abstract</p> <p>Background</p> <p>Mortality from cardiovascular disease in Estonia is among the highest in Europe. The reasons for this have not been clearly explained. Also, there are no studies available examining outpatient drug utilization patterns in patients wh...
Main Authors: | Baburin Aleksei, Marandi Toomas, Ainla Tiia |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-06-01
|
Series: | BMC Public Health |
Online Access: | http://www.biomedcentral.com/1471-2458/10/358 |
Similar Items
-
Changes in treatment and mortality of acute myocardial infarction in Estonian tertiary and secondary care hospitals in 2001 and 2007
by: Blöndal Mai, et al.
Published: (2012-01-01) -
Sex-specific outcomes of diabetic patients with acute myocardial infarction who have undergone percutaneous coronary intervention: a register linkage study
by: Blöndal Mai, et al.
Published: (2012-08-01) -
Utilization and Impact of Pharmacotherapy for Secondary Prevention after Acute Myocardial Infarction (AMI)
by: I-FangChen, et al.
Published: (2012) -
Assessment of serum prolactin levels in acute myocardial infarction: The role of pharmacotherapy
by: Hayder M Al-Kuraishy, et al.
Published: (2016-01-01) -
Trends in cervical cancer incidence and survival in Estonia from 1995 to 2014
by: Kristiina Ojamaa, et al.
Published: (2018-11-01)